Strongbridge Biopharma plc
SBBP evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Lead Asset:
- keveyis (Approved)
What it means
What to watch
Prepared research question
What matters most for SBBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 3 pipeline candidates · 1 FDA decision for Strongbridge Biopharma plc.
Similar companies
Run Strongbridge Biopharma plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Strongbridge Biopharma plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is Strongbridge Biopharma plc's lead drug candidate?
Strongbridge Biopharma plc's most advanced tracked candidate is keveyis (Approved) for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.
Who is the CEO of Strongbridge Biopharma plc?
John H. Johnson is the chief executive officer of Strongbridge Biopharma plc (SBBP).
What therapeutic areas does Strongbridge Biopharma plc focus on?
Strongbridge Biopharma plc develops therapies across Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.